logo
Plus   Neg
Share
Email

Teva To Discontinue Fremanezumab Development Program - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA) said it is discontinuing the clinical development program for use of fremanezumab in cluster headaches as a pre-specified futility analysis of a Phase III study showed that the primary endpoint is unlikely to be met. Also, Teva is stopping the ENFORCE Phase III clinical trial program.

Teva said it continues to explore other uses for fremanezumab, including the treatment of post-traumatic headache.

Fremanezumab is an investigational compound in the treatment of cluster headache or post-traumatic headache.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Whole Foods Market stores have recalled Decorated Red Apple Cookies as they may contain undeclared egg. People who have an allergy or severe sensitivity to these allergens run the risk of serious or life-threatening allergic reaction if they consume these products. The cookies were sold by the... Norwex has announced voluntary recall of about 58,000 rubber brooms due to laceration hazard. According to the company, handles of the recalled brooms can break in half, exposing a metal inner rim, posing a laceration hazard to the user. The recall involves extendable indoor/outdoor white rubber... Amazon.com Inc. has expanded its AmazonFresh grocery delivery service to three new cities. Beginning today, Amazon Prime members in Houston, Minneapolis and Phoenix can shop thousands of products, ranging from meat and seafood to fresh produce and everyday essentials. The groceries will be delivered to their homes in two hours or less, with options for one-hour and two-hour delivery.
Follow RTT